Solute carrier (SLC) family transporters utilize an electrochemical potential difference or an
ion gradient generated by primary active transporters for transporting their substrates across …

This review provides a practical clinical perspective on the relevance of hepatic transporters
in pharmacokinetics and drug‐drug interactions (DDIs). Special emphasis is placed on …

Objectives Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral
agent targeting the 3-chymotrypsin–like cysteine protease enzyme (3C-like protease or …

Pulmonary arterial hypertension (PAH) is a life-threatening and progressive disease of
various origins characterized by pulmonary vascular remodeling that leads to increased …

OATP1B1 and OATP1B3 are transporters that are expressed on the sinusoidal membrane of
hepatocytes; they accept a number of therapeutic reagents as their substrates. In vitro and in …

Human immunodeficiency virus (HIV)-associated heart disease encompasses a broad
spectrum of diseases. HIV infection may involve the pericardium, myocardium, coronary …

Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A
low dose of ritonavir is added to other protease inhibitors to take advantage of potent …

Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of
pulmonary arterial hypertension (PAH). Its use is limited by drug‐induced liver injury (DILI) …

The authors review the basic pharmacology and potential for adverse drug‐drug interactions
(DDIs) of bosentan and ambrisentan, the 2 endothelin receptor antagonists currently …

Advances in antiretroviral therapy have turned HIV into a chronic, manageable disease.
Patients often require treatment for co-morbid conditions as well as HIV, and consequently …